Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. \DE\LNDC · Entity 6447 | Vice President | October 17, 2019 | October 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIFECORE BIOMEDICAL, INC. \DE\
Report date October 17, 2019 · Filed October 17, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No Security beneficially ownedSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2019-10-17 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 0 |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.35 · Expires 2025-07-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F1: The options vest as to 1/36 of the total shares monthly, beginning on August 25, 2018, subject to continued service through each vesting date. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2023-05-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · Balance Not disclosed F4: The options vest as to (a) 33% for first year beginning on May 25, 2017 and then (b) the remaining in 1/36 monthly installments over the following 24 months, subject to continued service through each vesting date. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.65 · Expires 2024-10-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 10
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 10 · Balance Not disclosed F5: The options vest as to 1/36 of the total shares monthly, beginning on November 19, 2017, subject to continued service through each vesting date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.35 · Expires 2025-07-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance Not disclosed F1: The options vest as to 1/36 of the total shares monthly, beginning on August 25, 2018, subject to continued service through each vesting date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2023-05-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance Not disclosed F4: The options vest as to (a) 33% for first year beginning on May 25, 2017 and then (b) the remaining in 1/36 monthly installments over the following 24 months, subject to continued service through each vesting date. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.65 · Expires 2024-10-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · Balance Not disclosed F5: The options vest as to 1/36 of the total shares monthly, beginning on November 19, 2017, subject to continued service through each vesting date. |
| Right to Buy Restricted Stock Units (RSU)SEC Table II · derivative / convertible security · Expires 2021-07-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance Not disclosed F3: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F2: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit. |
| Right to Buy Restricted Stock Units (RSU)SEC Table II · derivative / convertible security · Expires 2020-10-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · Balance Not disclosed F3: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F2: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2019-05-25 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance Not disclosed F3: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F2: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest as to 1/36 of the total shares monthly, beginning on August 25, 2018, subject to continued service through each vesting date.
F2: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit.
F3: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis.
F4: The options vest as to (a) 33% for first year beginning on May 25, 2017 and then (b) the remaining in 1/36 monthly installments over the following 24 months, subject to continued service through each vesting date.
F5: The options vest as to 1/36 of the total shares monthly, beginning on November 19, 2017, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2019 Filed May 28, 2019 21:42 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-19-007268 · wf-form4_155907975494366.xml · derivative · entry 3 Javid Parker K · CIK 0001748560 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F2 · shares: The restricted stock units were granted on May 25, 2016. F3 · derivative.exercise_date: The restricted stock units vested on May 25, 2019. Read SEC document |
| May 25, 2019 Filed May 28, 2019 21:42 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Tax withholdingCommon Stock | 3,528 | $9.42 | $33,233.76 |
DisclosureSEC source: 0001628280-19-007268 · wf-form4_155907975494366.xml · nonDerivative · entry 2 Javid Parker K · CIK 0001748560 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,472 F1 · price: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
| May 25, 2019 Filed May 28, 2019 21:42 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 10,000 | $9.42 | $94,200.00 |
DisclosureSEC source: 0001628280-19-007268 · wf-form4_155907975494366.xml · nonDerivative · entry 1 Javid Parker K · CIK 0001748560 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. Read SEC document |
| January 30, 2019 Filed Jan 31, 2019 19:32 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 3,631 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-001586 · rdgdoc.xml · derivative · entry 1 Javid Parker K · CIK 0001748560 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,631 Underlying: Common Stock · 3,631 shares Expires 2022-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F1 · price: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.exercise_date: Restricted Stock Units will be automatically settled in shares of common stock subject to achievement of the performance goals set forth in the Company's LTIP for 2021. Read SEC document |
| January 30, 2019 Filed Feb 12, 2019 01:45 UTC Amendment | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 3,631 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-002267 · rdgdoc.xml · derivative · entry 1 Javid Parker K · CIK 0001748560 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,631 Underlying: Common Stock · 3,631 shares Expires 2021-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F1 · price: The Restricted Stock Units convert into Common Stock of Landec Corporation on a 1 for 1 basis. F2 · derivative.exercise_date: Restricted Stock Units will be automatically settled in shares of common stock subject to achievement of the performance goals set forth in the Company's LTIP for 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.